1.16 USD
▼-0.14-10.77%
盘后 1.12 -3.45%
2026-11-20
市值
$20.07M
市盈率
—
EPS
-41.46
股息率
—
52 周区间
1.01 – 12.60
成交量
60.67K
Beta
1.27
目标价
—
52W 低 1.0152W 高 12.60
价格走势
公司简介
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical...